Drugs / Cytokine-Induced Memory-like Natural Killer Cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05629546 | Nov 2024 → Feb 2029 expected | metastatic melanoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06321484 | Oct 2024 → Nov 2026 expected | ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, refractory malignant neoplasm | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06152809 | Feb 2024 → Nov 2026 expected | acute myeloid leukemia | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06138587 | Jan 2024 → Feb 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytokine Induced Memory-like Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06138587 ↗ |
| Known as | CIML NK | “CIML NK (cellular therapy)” NCT06321484 ↗ |
| Modality | Cell therapy | “CIML NK cells intravenous infusion (cellular therapy)” NCT06138587 ↗ |
| Route | Intravenous | “IV infusion of ML NK cells” NCT05629546 ↗ |